Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
VENUSREM.NS
Strong BuyFull HouseVenus Remedies Limited · Healthcare · India · $229M · Avg Vol: $647K/d
99
StockRankGet insider-trade alerts
Q
82
V
54
M
87
P/E (TTM)
19.0x
ROE
15.5%
D/E
0.0x
Dividend %
0.6%
COMPANY DESCRIPTION
Venus Remedies Limited engages in the pharmaceutical business in India, Latin America, Europe, the Middle East, Africa, Asia, and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 5.5B | 5.9B | 6.5B | 7.3B | 9.9% | 8.1B |
| EPS (INR) | 19.88 | 21.31 | 33.90 | 76.90 | 57.0% | 86.95 |
| Shares | 13.4M | 13.4M | 13.4M | 13.4M | 0.0% | 13.4M |
| Debt | 422.9M | 413.3M | 16.9M | 124.1M | -33.6% | 124.1M |
| Equity | 4.6B | 4.9B | 5.6B | 6.6B | 13.0% | — |
| Op CF | 366.3M | 372.9M | 864.4M | 1.6B | 62.0% | 1.6B |
| Inv CF | -508.3M | -72.1M | -762.5M | -1.8B | — | — |
| Fin CF | -5.7M | -10.8M | -10.2M | -31.2M | — | — |
Loading 1Y...
PRICE (1Y)+3.6%
SMA 50SMA 200
Close
$17.35
RSI (14)
38.1
52W High
$21.36
From 52W High
0.8%
SCORE BREAKDOWN
Quality
82
ROIC
21.9%91.9
ROE
15.5%82.7
GP/Assets
48.5%85.4
Op. Margin
15.3%75.5
FCF/Assets
13.8%92.3
Piotroski
668.8
Int. Cover
50.0x89.2
D/E Ratio
0.02x80.2
Current Ratio
2.44x47.4
Value
54
P/E (TTM)
19.0x62.5
EV/EBITDA
12.5x58.4
P/FCF
18.5x64.5
P/B
3.3x42.3
P/S
2.7x59.8
Div Yield
0.6%18.6
Momentum
87
52W High %
81%68.8
RS 6M
124%98.1
SMA 50/200
1.46x97.2
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
139%87.7
FUNDAMENTALS
Market Cap
$229M
P/E (Forward)
—
Gross Margin
51.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VENUSREM.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VENUSREM.NS | Venus Remedies Limited(you) | $229M | 99 | Strong Buy |
| SYNCOMF.NS | Syncom Formulations (India) Limited | $208M | 96 | Strong Buy |
| LINCOLN.NS | Lincoln Pharmaceuticals Limited | $135M | 99 | Strong Buy |
| JAGSNPHARM.NS | Jagsonpal Pharmaceuticals Limited | $165M | 94 | Strong Buy |
| WINDLAS.NS | Windlas Biotech Limited | $248M | 84 | Strong Buy |
| ANUHPHR.NS | Anuh Pharma Limited | $101M | 94 | Strong Buy |
| SAKAR.NS | Sakar Healthcare Limited | $268M | 79 | Buy |
| UNICHEMLAB.NS | Unichem Laboratories Limited | $413M | 87 | Strong Buy |
| INDSWFTLAB.NS | Ind-Swift Laboratories Limited | $356M | 81 | Strong Buy |
| SOLARA.NS | Solara Active Pharma Sciences Limited | $357M | 81 | Strong Buy |
Peer medians: ROE 11.8% · P/E 42.8x · Gross margin 59.4%